TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9569075
Drug: Oral prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone (OP) initial dose 15 mg, gradually tapering
Study: 9569075
Drug: Intramuscular methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular methylprednisolone acetate (i.m. MP)
Study: 8547555
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of intrapleural morphine (IPM group)
Study: 8547555
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of intravenous morphine (IVM group)
Study: 523421
Drug: Ethambutol (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethambutol (25 mg/kg daily) for 8 days in healthy subjects
Study: 31896529
Drug: Antidepressant medications
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant medications (ADM)
Study: 31896529
Drug: Both Antidepressant
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both Antidepressant medications (ADM) and Cognitive therapy (CT)
Study: 30611343
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of 15 mg/kg of tranexamic acid (TXA)
Study: 28278717
Drug: Directly observed
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Directly observed therapy (DOT) with intermittent, high-dose Vitamin D3
Study: 25443996
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (n=42): psychotherapy, pharmaceutical interventions, and group therapy.
Study: 19760753
Drug: Phlebotomies to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phlebotomies to obtain a ferritin level <50 ng/mL followed by pegylated‐Interferon alpha2b + ribavirin
Study: 19760753
Drug: Phlebotomies and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phlebotomies and antiviral therapy
Study: 9389947
Drug: Clindamycin hydrochloride
Normalized name: Clindamycin Hydrochloride
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clindamycin hydrochloride capsules, 150 mg by mouth four times daily for 7 consecutive days.
Study: 9389947
Drug: Placebo (partner
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (partner treatment).
Study: 9389947
Drug: Clindamycin hydrochloride
Normalized name: Clindamycin Hydrochloride
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clindamycin hydrochloride capsules, 150 mg by mouth four times daily for 7 consecutive days (among women cured by the first week's visit).
Study: 9389947
Drug: Placebo (partner
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (partner treatment, among women cured by the first week's visit).
Study: 7707159
Drug: Twice a
Normalized name: Pataday Twice A Day Relief
DrugBank: Olopatadine (DB00768)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice a day slow-release nifedipine
Study: 29100903
Drug: Antibiotics (n=34)
Normalized name: N-(3,4-Dimethoxycinnamoyl)anthranilic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics (n=34)
Study: 29100903
Drug: Antibiotics (n=32)
Normalized name: N-Vanillylnonamide
DrugBank: Nonivamide (DB11324)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics (n=32)
Study: 23876062
Drug: Capecitabine (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capecitabine (1000 mg/m2 orally BID, days 1 to 14 of 21) in combination with Sorafenib (600 mg/day orally BID, days 1 to 21)
Study: 18180683
Drug: Cyclosporine 0.05%
Normalized name: CYCLOSPORINE 0.05% (PF) EMULSION,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine 0.05% ophthalmic emulsion (Restasis; Allergan, Inc.) used twice daily
Study: 18180683
Drug: Placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo group receiving rewetting drops (Refresh Preservative Free Artificial Tears; Allergan, Inc.) used twice daily
Study: 11729030
Drug: 3 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g/day ethyl eicosapentaenoic acid (EPA)
Study: 8269914
Drug: Thiamine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiamine (50 mg/day)
Study: 8269914
Drug: Placebo (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (two tablets per day)
Study: 2957348
Drug: Amoxycillin 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxycillin 1.0 g intramuscularly
Study: 30033356
Drug: Lorcaserin 10mg,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorcaserin 10mg, twice a day for 24 weeks
Study: 22658268
Drug: Osteopathic Manipulative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osteopathic Manipulative Treatment (OMT) + Specific Exercises (SE)
Study: 7829604
Drug: GH treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH treatment (0.2 IU/kg.week for 6 months)
Study: 334471
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg phenylbutazone
Study: 334471
Drug: 2.1 g
Normalized name: GLYCERIN 2.1 g RECTAL SUPPOSITORY
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.1 g aspirin
Study: 31104056
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D 2,000 IU tablet every other day for 12 weeks
Study: 15060509
Drug: lopinavir (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: lopinavir (400 mg twice daily) and ritonavir (100 mg twice daily)
Study: 15060509
Drug: amprenavir (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: amprenavir (600 mg twice daily) plus ritonavir (100 mg twice daily)
Study: 15060509
Drug: lopinavir (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: lopinavir (400 mg twice daily) and ritonavir (100 mg twice daily) plus additional ritonavir (100 mg twice daily)
Study: 15060509
Drug: amprenavir (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: amprenavir (600 mg twice daily) plus ritonavir (200 mg twice daily)
Study: 8154531
Drug: Lodoxamide 0.1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lodoxamide 0.1% ophthalmic solution
Study: 31180819
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy with oral tegafur-uracil
Study: 25707402
Drug: Lowest 1,25(OH)2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lowest 1,25(OH)2 D levels (8.70 to 51.60 pg/mL)
Study: 19622108
Drug: Rectal diclofenac
Normalized name: diclofenac Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal diclofenac 100 mg (Group 1, n = 19)
Study: 19622108
Drug: Placebo suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo suppository (Group 2, n = 18)
Study: 19622108
Drug: Rectal diclofenac
Normalized name: diclofenac Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal diclofenac (Group 1)
Study: 17387026
Drug: Paracetamol 1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol 1000 mg three times daily
Study: 15596757
Drug: Pregabalin (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin (300 mg/day and 600 mg/day)
Study: 9404176
Drug: nalbuphine 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: nalbuphine 0.1 mg.kg‐1
Study: 9404176
Drug: pethidine 1
Normalized name: Pethidine
DrugBank: Meperidine (DB00454)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: pethidine 1 mg.kg‐1
Study: 8424396
Drug: Mitomycin plus
Normalized name: Mitomycin
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mitomycin plus high-dose medroxyprogesterone acetate (MMPA)
Study: 31257067
Drug: Tailored therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tailored therapy (PPI, amoxicillin, and clarithromycin for 7 days; PPI, amoxicillin, and levofloxacin for 10 days; PPI, amoxicillin, and metronidazole for 14 days)
Study: 31257067
Drug: Empirical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empirical therapy (PPI, amoxicillin, and clarithromycin for 7 days)
Study: 26509763
Drug: Gatifloxacin 0.3%
Normalized name: GATIFLOXACIN 0.3% SOLN,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gatifloxacin 0.3% (monotherapy)
Study: 26509763
Drug: Fortified cefazolin
Normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fortified cefazolin sodium 5% and tobramycin sulfate 1.3% (combination therapy)
Study: 25327732
Drug: YAZ (drospirenone
Approvals — FDA: no, EMA: no, PMDA: no
Description: YAZ (drospirenone 3 mg and ethinylestradiol 20 µg)
Study: 21038654
Drug: Shenyanning (SYN)
Normalized name: Gel-Syn
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shenyanning (SYN) Decoction, one dose per day for 1 year
Study: 21038654
Drug: Losartan (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan (50 mg per day for 1 year)
Study: 2646418
Drug: 7% tetrapotassium
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7% tetrapotassium peroxydiphosphate (PDP) solution administered as a subgingival irrigant
Study: 2646418
Drug: Placebo rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo rinse similar to the test solution, but without PDP
Study: 2646418
Drug: 7% tetrapotassium
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7% tetrapotassium peroxydiphosphate (PDP) solution
Study: 788739
Drug: Phenylbutazone 50
Normalized name: Phenylbutazone
DrugBank: Phenylbutazone (DB00812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phenylbutazone 50 mg/day
Study: 788739
Drug: Phenylbutazone 100
Normalized name: phenylbutazone 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylbutazone 100 mg/day
Study: 788739
Drug: Phenylbutazone 200
Normalized name: phenylbutazone 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylbutazone 200 mg/day
Study: 913873
Drug: Phenylbutazone 400
Normalized name: Phenylbutazone
DrugBank: Phenylbutazone (DB00812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phenylbutazone 400 mg/day
Study: 913873
Drug: Phenylbutazone (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylbutazone (all doses)
Study: 913873
Drug: Phenylbutazone 50
Normalized name: Phenylbutazone
DrugBank: Phenylbutazone (DB00812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phenylbutazone 50 and 100 mg/day
Study: 913873
Drug: Phenylbutazone 200
Normalized name: phenylbutazone 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylbutazone 200 and 400 mg/day
Study: 31704518
Drug: Anodal transcranial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anodal transcranial direct current stimulation (tDCS) over the left inferior frontal gyrus combined with written naming/spelling therapy
Study: 31704518
Drug: Sham tDCS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham tDCS over the left inferior frontal gyrus combined with written naming/spelling therapy
Study: 27876449
Drug: Paraffin therapy
Normalized name: Paraffin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paraffin therapy (n = 27)
Study: 27876449
Drug: Placebo therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo therapy (n = 25)
Study: 23939631
Drug: Sotatercept 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sotatercept 1 mg/kg
Study: 21291564
Drug: Decentralised and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decentralised and non-specialised standard psychiatric treatment
Study: 19524906
Drug: 200mg of
Normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200mg of oral iron tablets 3 times a day for 4 weeks
Study: 11158764
Drug: Trovafloxacin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trovafloxacin (200 mg)
Study: 8509683
Drug: diclofenac sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: diclofenac sodium 0.1% eye drops (Voltaren Ophthalmic)
Study: 20437564
Drug: Monthly gadolinium-enhanced
Normalized name: gadolinium
DrugBank: Gadolinium (DB12091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly gadolinium-enhanced T1-weighted (Gd-T1w) imaging
Study: 16165718
Drug: Oral ferrous
Normalized name: ferrous fumarate Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ferrous fumarate (Neo‐fer) 120 mg orally once daily
Study: 16165718
Drug: Intravenous iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous iron sucrose (Venofer) 200 mg intravenously 3 times during a period of 14 days
Study: 10809863
Drug: Odorants with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Odorants with a sedative effect
Study: 519476
Drug: Praziquantel 30
Normalized name: praziquantel 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Praziquantel 30 mg/kg
Study: 2005563
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of lidocaine, epinephrine, hyaluronidase with bupivacaine
Study: 6519165
Drug: Lasix (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lasix (40 mg)
Study: 6519165
Drug: Furix (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furix (40 mg)
Study: 29458928
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 (28,000 IU weekly for 8 weeks)
Study: 24881917
Drug: Methotrexate 1
Normalized name: methotrexate 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate 1 g/m(2) over 24 hours with intrathecal injection (MTX1 arm)
Study: 24881917
Drug: Methotrexate 3
Normalized name: methotrexate 37.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate 3 g/m(2) over 3 hours without intrathecal injection (MTX3 arm)
Study: 24881917
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment in Japan (both MTX1 and MTX3 arms)
Study: 24881917
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment in international study (both MTX1 and MTX3 arms)
Study: 22552038
Drug: 20 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 μg vitamin D3 daily for 10 weeks
Study: 22552038
Drug: 7 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 μg 25-hydroxyvitamin D3 daily for 10 weeks
Study: 22552038
Drug: 20 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 μg 25-hydroxyvitamin D3 daily for 10 weeks
Study: 17388752
Drug: Cyproheptadine hydrochloride
Normalized name: Cyproheptadine Hydrochloride
DrugBank: Cyproheptadine (DB00434)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cyproheptadine hydrochloride (CH) 2 mg QID for 1 week followed by 4 mg QID for 11 weeks
Study: 15576390
Drug: rLH supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: rLH supplementation (150 IU) in addition to rFSH (225 IU starting dose)
Study: 15576390
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (normal responders with rFSH monotherapy)
Study: 9466083
Drug: Metronidazole 1
Normalized name: metronidazole 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole 1 percent cream applied once daily
Study: 8595079
Drug: Topical anaesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical anaesthesia with liposomal gel formulation containing 2% tetracaine
Study: 8595079
Drug: In vitro
Normalized name: glucuronidase in vitro test
Approvals — FDA: no, EMA: no, PMDA: no
Description: In vitro drug liberation
Study: 1974941
Drug: Methylfolate, 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylfolate, 15 mg daily for 6 months in addition to standard psychotropic treatment
Study: 30003324
Drug: Ibuprofen gel
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen gel phonophoresis
Study: 30003324
Drug: Ibuprofen cream
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen cream phonophoresis
Study: 26582047
Drug: Ketamine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (0.5 mg/kg at induction, followed by 0.25 mg/kg/h continuous infusion for 30 min)
Study: 26582047
Drug: Control (0.9%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (0.9% saline, 0.05 ml/kg at induction, followed by 0.025 ml/kg/h continuous infusion for 30 min)
Study: 22997792
Drug: Acupotomy treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupotomy treatment once a week for 3 weeks.
Study: 22997792
Drug: Electroacupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroacupuncture treatment 3 times a week for 3 weeks.
Study: 20332722
Drug: Conventional neuro-rehabilitation
Normalized name: MV Neuro
DrugBank: MV-NB-02 (DB17305)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional neuro-rehabilitation protocol (therapeutic exercise and occupational therapy) plus 60 minutes of mental practice training for 3 weeks
Study: 20332722
Drug: Conventional neuro-rehabilitation
Normalized name: MV Neuro
DrugBank: MV-NB-02 (DB17305)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional neuro-rehabilitation protocol (therapeutic exercise and occupational therapy) for 3 weeks
Study: 10077172
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with recombinant interferon-alpha2b (rIFN-alpha2b) and zidovudine (ZDV)
Study: 6938242
Drug: New drug
Normalized name: varicella zoster immune globulin (Investigational New Drug)
Approvals — FDA: no, EMA: no, PMDA: no
Description: New drug combination (cincain chloride, tri‐iodomethane, tranexamic acid, propyl‐hydroxy‐benzoic acid in Gelfoam)
Study: 26189808
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment (rotator cuff repair)
Study: 26189808
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment (rotator cuff repair) without retear
Study: 21057805
Drug: Ranibizumab-based therapy
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ranibizumab-based therapy
Study: 19054783
Drug: 100 mg/day
Normalized name: infigratinib phosphate 100 mg/day (100 mg x 1) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg/day soy isoflavones
Study: 15539961
Drug: Atorvastatin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (10 mg q x d)
Study: 1888695
Drug: Benazepril (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benazepril (10 mg once daily)
Study: 1758250
Drug: IG/IH nerve
Approvals — FDA: no, EMA: no, PMDA: no
Description: IG/IH nerve block (0.25% bupivacaine, 1 mg/kg)
Study: 1758250
Drug: Intravenous fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous fentanyl (1 microgram/kg)
Study: 7117428
Drug: Combined oral
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined oral and inhalation salbutamol
Study: 7117428
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (oral and inhalation)
Study: 30659063
Drug: Acceptance and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acceptance and Commitment Therapy (ACT) plus asthma education
Study: 25181946
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg prednisolone per day, tapered to 5 mg over 8 weeks
Study: 25181946
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg prednisolone per day, tapered to 5 mg over 8 weeks
Study: 25181946
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg prednisolone per day
Study: 25181946
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg prednisolone per day
Study: 22909076
Drug: self‐administered relaxation
Approvals — FDA: no, EMA: no, PMDA: no
Description: self‐administered relaxation acupressure
Study: 22909076
Drug: self‐administered stimulating
Approvals — FDA: no, EMA: no, PMDA: no
Description: self‐administered stimulating acupressure
Study: 18946667
Drug: Lemon juice
Normalized name: lemon juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lemon juice (60 mEq/day, approximately 85 cc/day)
Study: 11802748
Drug: 5-day treatment
Normalized name: 30 day Acne Treatment Kit KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-day treatment with 3 antibiotics (amoxicillin 1 g bid, clarithromycin 250 mg bid, metronidazole 400 mg bid) and lansoprazole 30 mg bid (L5)
Study: 11802748
Drug: 3-day antibiotic-lansoprazole
Normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3-day antibiotic-lansoprazole combination (L3) with a 2-day pretreatment with lansoprazole
Study: 11802748
Drug: 5-day treatment
Normalized name: 30 day Acne Treatment Kit KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-day treatment with 3 antibiotics and ranitidine hydrochloride 300 mg bid (R5)
Study: 10621929
Drug: Herbal remedy
Normalized name: Hyperici herba
DrugBank: St. John's Wort (DB01323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herbal remedy (Radix echinaceae, Radix baptisiae, Herba thujae), 3 tablets t.i.d. for 7 to 9 days
Study: 8565486
Drug: Empty patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empty patch
Study: 6874890
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg testosterone enanthate
Study: 6874890
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg testosterone enanthate
Study: 31072850
Drug: Stretching/flexibility exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stretching/flexibility exercise programme combined with placebo supplements
Study: 29863974
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose of cyclophosphamide
Study: 23281754
Drug: D, L-propargylglycerine
Approvals — FDA: no, EMA: no, PMDA: no
Description: D, L-propargylglycerine (CSE inhibitor)
Study: 14760111
Drug: Exemestane (E)
Normalized name: Exemestane
DrugBank: Exemestane (DB00990)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exemestane (E) 25 mg once daily
Study: 14760111
Drug: Tamoxifen (T)
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tamoxifen (T) 20 mg once daily
Study: 11142488
Drug: Verapamil (VER)
DrugBank: Verapamil (DB00661)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Verapamil (VER) 240 mg/day divided in 2 doses, from day 1 to day 28 of each cycle
Study: 9187418
Drug: Pravastatin 10
Normalized name: pravastatin 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin 10 mg/day starting at day 3, increasing to 20 mg/day for 3 months
Study: 22160628
Drug: Standard Support
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Support Therapy (SST)
Study: 20642391
Drug: Atomoxetine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atomoxetine treatment at Week 8